Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical and genetic spectrum of a large cohort of patients with δ-sarcoglycan muscular dystrophy

  • Alonso Pérez, Jorge|||0000-0001-8866-5186
  • González Quereda, Lidia|||0000-0003-0715-6414
  • Bruno, Claudio
  • Panicucci, Chiara
  • Alavi, Afagh
  • Nafissi, Shahriar
  • Nilipour, Yalda
  • Zanoteli, Edmar
  • Isihi, Lucas Michielon de Augusto
  • Melegh, Béla
  • Hadzsiev, Kinga
  • Muelas, Nuria|||0000-0002-2349-7481
  • Vílchez, Juan J.|||0000-0002-0532-2872
  • Dourado, Mario Emilio
  • Kadem, Naz
  • Kutluk, Gultekin
  • Umair, Muhammad|||0000-0001-6729-9746
  • Younus, Muhammad
  • Pegorano, Elena
  • Bello, Luca|||0000-0002-3075-6525
  • Crawford, Thomas O.
  • Suarez-Calvet, Xavier|||0000-0002-5314-6607
  • Töpf, Ana
  • Guglieri, Michela|||0000-0002-8455-0637
  • Marini-Bettolo, Chiara|||0000-0003-3795-6017
  • Gallano, Pia|||0000-0001-8104-2197
  • Straub, Volker|||0000-0001-9046-3540
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
Sarcoglycanopathies include four subtypes of autosomal recessive limb-girdle muscular dystrophies (LGMDR3, LGMDR4, LGMDR5 and LGMDR6) that are caused, respectively, by mutations in the SGCA, SGCB, SGCG and SGCD genes. Delta-sarcoglycanopathy (LGMDR6) is the least frequent and is considered an ultra-rare disease. Our aim was to characterize the clinical and genetic spectrum of a large international cohort of LGMDR6 patients and to investigate whether or not genetic or protein expression data could predict a disease's severity. This is a retrospective study collecting demographic, genetic, clinical and histological data of patients with genetically confirmed LGMDR6 including protein expression data from muscle biopsies. We contacted 128 paediatric and adult neuromuscular units around the world that reviewed genetic data of patients with a clinical diagnosis of a neuromuscular disorder. We identified 30 patients with a confirmed diagnosis of LGMDR6 of which 23 patients were included in this study. Eighty-seven per cent of the patients had consanguineous parents. Ninety-one per cent of the patients were symptomatic at the time of the analysis. Proximal muscle weakness of the upper and lower limbs was the most common presenting symptom. Distal muscle weakness was observed early over the course of the disease in 56.5% of the patients. Cardiac involvement was reported in five patients (21.7%) and four patients (17.4%) required non-invasive ventilation. Sixty per cent of patients were wheelchair-bound since early teens (median age of 12.0 years). Patients with absent expression of the sarcoglycan complex on muscle biopsy had a significant earlier onset of symptoms and an earlier age of loss of ambulation compared to patients with residual protein expression. This study confirmed that delta-sarcoglycanopathy is an ultra-rare neuromuscular condition and described the clinical and molecular characteristics of the largest yet-reported collected cohort of patients. Our results showed that this is a very severe and quickly progressive disease characterized by generalized muscle weakness affecting predominantly proximal and distal muscles of the limbs. Similar to other forms of sarcoglycanopathies, the severity and rate of progressive weakness correlates inversely with the abundance of protein on muscle biopsy. Alonso-Pérez et al. describe the largest cohort to date of patients with the ultra-rare neuromuscular disorder delta-sarcoglycanopathy, and show that the severity and rate of progressive weakness correlates inversely with the abundance of protein expression on muscle biopsy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Isolation of human fibroadipogenic progenitors and satellite cells from frozen muscle biopsies

  • Suarez-Calvet, Xavier|||0000-0002-5314-6607
  • Fernández Simón, Esther|||0000-0003-4804-6553
  • Piñol-Jurado, Patricia|||0000-0002-2757-5758
  • Alonso Pérez, Jorge|||0000-0001-8866-5186
  • Carrasco-Rozas, Ana|||0000-0003-2165-8162
  • Lleixà, Cinta|||0000-0002-9971-0584
  • López-Fernández, Susana
  • Pons, Gemma|||0000-0001-8803-5432
  • Soria, L.
  • Bigot, Anne|||0000-0003-0337-5425
  • Mouly, V.
  • Illa, Isabel|||0000-0002-2186-2684
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Jaiswal, JK.|||0000-0002-5992-5185
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
Skeletal muscle contains multiple cell types that work together to maintain tissue homeostasis. Among these, satellite cells (SC) and fibroadipogenic progenitors cells (FAPs) are the two main stem cell pools. Studies of these cells using animal models have shown the importance of interactions between these cells in repair of healthy muscle, and degeneration of dystrophic muscle. Due to the unavailability of fresh patient muscle biopsies, similar analysis of interactions between human FAPs and SCs is limited especially among the muscular dystrophy patients. To address this issue here we describe a method that allows the use of frozen human skeletal muscle biopsies to simultaneously isolate and grow SCs and FAPs from healthy or dystrophic patients. We show that while the purified SCs differentiate into mature myotubes, purified FAPs can differentiate into adipocytes or fibroblasts demonstrating their multipotency. We find that these FAPs can be immortalized and the immortalized FAPs (iFAPs) retain their multipotency. These approaches open the door for carrying out personalized analysis of patient FAPs and interactions with the SCs that lead to muscle loss.